1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Vital Signs The Analyst's Perspective - October 2015 Issue

Vital Signs The Analyst's Perspective - October 2015 Issue

  • December 2015
  • -
  • Frost & Sullivan
  • -
  • 5 pages

Summary

Table of Contents

2015 Mammogram Guidelines Have Changed
Source: Journal of American Medical Association, October 20, 2015
On October 20, 2015, the American Cancer Society (ACS) announced an update to its recommended breast cancer screening guidelines for women with average risk of breast cancer. In the new guidelines, the ACS
recommended that “most women should begin annual screening at age 45 instead of age 40, and switch to every other year at age 55.” Mammograms can yield false-positive results, requiring additional testing or over
testing. Also, mammograms can detect very low-risk cancers that would never cause women health problems had they never been treated, resulting in many women receiving treatment who would not have otherwise
needed it, hence, over treatment.

The Analyst’s Perspective by Barbara Gilmore, Senior Industry Analyst, Life Sciences
The ACS is recommending screening for various cancers in an effort to detect cancers early, when they are easier to treat and cure. Breast cancer is the second-leading cause of cancer death in women in the United
States, and preventative screening can be beneficial. The sooner cancers can be diagnosed and treated, the higher the chance of survival or cure. In the US, there are different screening recommendations coming
from different organizations. In 2009, the US Preventative Services Task Force (USPSTF) recommended and currently recommends that women do not start getting breast mammograms until age , and then only get
screened every two years, because too many screens may lead to over diagnosis and over treatment. The ACS recommends women should be screened more frequently based on their belief that screening catches cancers at earlier stages.

What does this mean? In the long run, large sums of money will be saved with the reduced numbers of mammograms and unnecessary over treatments. Until 2015, most studies of breast cancer screening had
been performed on women older than years in the Medicare population. In 2015, physicians at Harvard Medical School and Boston Children’s studied the costs of false-positive mammograms and breast cancer over
diagnoses among women aged , based on expenditure data from a major US healthcare insurance plan for the years 2011-2013. The costs associated with false-positive mammograms and over diagnoses were
reported to be in excess of $ billion per year. It is important for women to recognize the risk factors for breast cancer, including a genetic predisposition, breast density, and family history, in making decisions about
how frequently they would have breast screens. Knowledge of the total picture will help physicians make their patient care more personalized. The women who are most at risk and would benefit from the screening should be screened. The costs associated with screening and over treatment are substantial. How much money will be saved? Time will tell.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

  • $ 6650
  • Industry report
  • March 2017
  • by BCC Research

Use this report to: - Analyze the global prostate cancer market, with important statistics and analysis on existing drugs, and diagnostic technologies. - Receive information on regulatory environment, ...

Prostate Cancer Therapeutics Market ; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Prostate Cancer Therapeutics Market ; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • March 2017
  • by Transparency Market Research

Global Prostate Cancer Therapeutics Market: Overview This report on the prostate cancer therapeutics market analyzes the current and future scenario of the global market. Increasing prevalence of prostate ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the Netherlands - Forecast

  • April 2017
    10 pages
  • Cancer  

  • Netherlands  

View report >

Endocrine Disease Statistics in the US

  • April 2017
    122 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Lung Cancer Statistics in Europe - Forecast

  • April 2017
    10 pages
  • Lung Cancer  

    Therapy  

  • Europe  

View report >

Cancer Statistics

10 days ago

Cancer Statistics

10 days ago

Related Market Segments :

Cancer
Breast Cancer

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.